A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
NCT ID: NCT05989048
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1414 participants
INTERVENTIONAL
2023-11-29
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is seeking for participants who:
* have at least 1 year of migraine history before entering the study.
* have 2 to 8 migraine headache attacks of moderate or severe intensity in each of the 3 months before entering the study.
* have less than 15 days with headaches in each of the 3 months before entering the study. The headaches could be either due to migraine or not.
The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity.
The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults.
Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
NCT05960032
Randomized Trial in Adult Participants With Acute Migraines
NCT04571060
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
NCT04804033
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
NCT06401642
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
NCT06103734
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zavegepant
Zavegepant intranasal 10 mg
Zavegepant
The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
Placebo
Placebo
Placebo
Single dose of matching placebo taken within Treatment Phase.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zavegepant
The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
Placebo
Single dose of matching placebo taken within Treatment Phase.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with minimum 1 year history of migraine (with or without aura) prior to the Screening Visit, consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
2. Migraine attacks, on average, lasting about 4-72 hours if untreated.
3. Not more than 8 attacks of moderate or severe pain intensity per month within last 3 months.
4. Participants must be able to distinguish migraine attacks from tension/cluster headaches.
5. At least 2 consistent migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and throughout the Screening Phase (participant self-report).
6. Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase (participant self-report).
7. Participants on prophylactic migraine medication are permitted to remain on therapy if they have been on a stable dose for at least 3 months prior to Screening Visit, and if the dose is not expected to change through the End of Treatment Visit.
8. Participants with contraindications for use of triptans may be included provided they meet all other study entry criteria.
Exclusion Criteria
* History or current evidence of uncontrolled, unstable or recently diagnosed cardiovascular or cardiometabolic disease.
* Major depressive disorder, anxiety disorder, or other significant psychiatric disorder.
* Acute or chronic pain syndromes, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that interfere with study assessments.
* Conditions that may affect the administration or absorption of the nasal product.
* Medication overuse headaches.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second People's hospital of Hefei
Hefei, Anhui, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Hainan General Hospital
Haikou, Hainan, China
Renmin Hospital Of Wuhan University
Wuhan, Hebei, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
People's Hospital of Zhengzhou
Zhengzhou, Henan, China
Wuhan Third Hospital
Wuhan, Hubei, China
Changsha Central Hospital
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
The Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
The People's Hospital of Liaoning Province
Shenyang, Liaoning, China
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, China
General Hospital of Ningxia Medical Hospital
Yinchuan, Ningxia, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Shaanxi Provincial People' Hospital
Xi'an, Shaanxi, China
Xian Gaoxin Hospital
Xi'an, Shaanxi, China
Xianyang Hospital of Yan'an University
Xianyang, Shaanxi, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Jinan Central Hospital
Jinan, Shandong, China
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
Liaocheng people's Hospital
Liaocheng, Shandong, China
Qingdao Central Hospital
Qingdao, Shandong, China
People's Hospital of Rizhao
Rizhao, Shandong, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Ruian People's Hospital
Rui’an, Zhejiang, China
The First Affiliated Hosptial of Wenzhou Medical University
Wenzhou, Zhejiang, China
Peking University People's Hospital
Beijing, , China
Xuanwu Hospital Capital Medical University
Beijing, , China
Chongqing University Three Gorges Hospital
Chongqing, , China
The fourth people's hospital of chongqing
Chongqing, , China
Shanghai East Hospital
Shanghai, , China
Tianjin Union Medical Center
Tianjin, , China
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Inje University - Ilsan Paik Hospital
Goyang-si, Kyǒnggi-do, South Korea
Hallym University Dongtan Sacred Heart Hospital
Hwaseong-si, Kyǒnggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, South Korea
The Catholic University of Korea, Uijeongbu St. Mary's Hospital
Uijeongbu-si, Kyǒnggi-do, South Korea
Dong-A University Hospital
Busan, Pusan-kwangyǒkshi, South Korea
Nowon Eulji Medical Center, Eulji University
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Asan Medical Center
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Ewha Womans University Seoul Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
Taipei Veterans General Hospital
Taipei, , Taiwan
Tri-Service General Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT05989048
Identifier Type: REGISTRY
Identifier Source: secondary_id
C5301008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.